Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften Toetsvragen Web-tv Video Audio
Tips voor Mijn BSL
Inloggen

Welkom bij Scalda & Bohn Stafleu van Loghum

Scalda heeft ervoor gezorgd dat je Mijn BSL eenvoudig en snel kunt raadplegen.Je kunt de producten hieronder links aanschaffen en rechts inloggen.

» Andere revante producten voor Scalda studenten en medewerkers.

Registreer

Schaf de BSL Academy aan: 

BSL Academy mbo AG

Eenmaal aangeschaft kun je thuis, of waar ook ter wereld toegang krijgen tot Mijn BSL.

Heb je een vraag, neem dan contact op met Jan van der Velden.

Login

Als u al geregistreerd bent, hoeft u alleen maar in te loggen om onbeperkt toegang te krijgen tot Mijn BSL.

Inloggen
Top
Quality of Life Research
Gepubliceerd in:

08-09-2022 | Special Section: Methodologies for Meaningful Change

“From Where I Stand”: using multiple anchors yields different benchmarks for meaningful improvement and worsening in the rheumatoid arthritis flare questionnaire (RA-FQ)

Auteurs: Susan J. Bartlett, Vivian P. Bykerk, Orit Schieir, Marie-France Valois, Janet E. Pope, Gilles Boire, Carol Hitchon, Glen Hazlewood, Louis Bessette, Edward Keystone, Carter Thorne, Diane Tin, Clifton O. Bingham III, CATCH Investigators

Gepubliceerd in: Quality of Life Research | Uitgave 5/2023

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Purpose

The Rheumatoid Arthritis Flare Questionnaire (RA-FQ) is a patient-reported measure of disease activity in RA. We estimated minimal and meaningful change from the perspective of RA patients, physicians, and using a disease activity index.

Methods

Data were from 3- to 6-month visits of adults with early RA enrolled in the Canadian Early Arthritis Cohort. Participants completed the RA-FQ, the Patient Global Assessment of RA, and the Patient Global Change Impression at consecutive visits. Rheumatologists recorded joint counts and MD Global. Clinical Disease Activity Index (CDAI) scores were computed. We compared mean RA-FQ change across categories using patients, physicians, and CDAI anchors.

Results

The 808 adults were mostly white (84%) women (71%) with a mean age of 55 and moderate-high disease activity (85%) at enrollment. At V2, 79% of patients classified their RA as changed; 59% were better and 20% were worse. Patients reporting they were a lot worse had a mean RA-FQ increase of 8.9 points, whereas those who were a lot better had a -6.0 decrease. Minimal worsening and improvement were associated with a mean 4.7 and − 1.8 change in RA-FQ, respectively, while patients rating their RA unchanged had stable scores. Physician and CDAI classified more patients as worse than patients, and minimal and meaningful RA-FQ thresholds differed by group.

Conclusion

Thresholds to identify meaningful change vary by anchor used. These data offer new evidence demonstrating robust psychometric properties of the RA-FQ and offer guidance about improvement or worsening, supporting its use in RA care, research, and decision-making.
vorige artikel Transitions in depression: if, how, and when depressive symptoms return during and after discontinuing antidepressants
volgende artikel Using qualitative methods to establish the clinically meaningful threshold for treatment success in alopecia areata
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
Myasoedova, E., Crowson, C. S., Kremers, H. M., Therneau, T. M., & Gabriel, S. E. (2010). Is the incidence of rheumatoid arthritis rising?: Results from Olmsted County, Minnesota, 1955–2007. Arthritis and Rheumatism, 62, 1576–1582.PubMedPubMedCentralCrossRef
2.
Myasoedova, E., Davis, J. M., 3rd., Crowson, C. S., & Gabriel, S. E. (2010). Epidemiology of rheumatoid arthritis: Rheumatoid arthritis and mortality. Current Rheumatology Reports, 12, 379–385.PubMedCrossRef
3.
Bartlett, S. J., Hewlett, S., Bingham, C. O., 3rd., Woodworth, T. G., Alten, R., Pohl, C., Choy, E. H., Sanderson, T., Boonen, A., Bykerk, V., et al. (2012). Identifying core domains to assess flare in rheumatoid arthritis: An OMERACT international patient and provider combined Delphi consensus. Annals of the Rheumatic Diseases, 71, 1855–1860.PubMedCrossRef
4.
Sanderson, T., Morris, M., Calnan, M., Richards, P., & Hewlett, S. (2010). Patient perspective of measuring treatment efficacy: The rheumatoid arthritis patient priorities for pharmacologic interventions outcomes. Arthritis Care Res (Hoboken), 62, 647–656.PubMedCrossRef
5.
Gossec, L., Dougados, M., Rincheval, N., Balanescu, A., Boumpas, D. T., Canadelo, S., Carmona, L., Daures, J. P., de Wit, M., Dijkmans, B. A., et al. (2009). Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: A EULAR initiative. Annals of the Rheumatic Diseases, 68, 1680–1685.PubMedCrossRef
6.
Ward, M. M. (2022). Trends in permanent work disability associated with rheumatoid arthritis in the United States, 1999–2015. Arthritis Care Res (Hoboken), 74, 1321–1324.PubMedCrossRef
7.
Bingham, C. O., III., Pohl, C., Woodworth, T. G., Hewlett, S. E., May, J. E., Rahman, M. U., Witter, J. P., Furst, D. E., Strand, C. V., Boers, M., & Alten, R. E. (2009). Developing a standardized definition for disease “flare” in rheumatoid arthritis (OMERACT 9 Special Interest Group). Journal of Rheumatology, 36, 2335–2341.PubMedCrossRef
8.
Myasoedova, E., Chandran, A., Ilhan, B., Major, B. T., Michet, C. J., Matteson, E. L., & Crowson, C. S. (2016). The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease. Annals of the Rheumatic Diseases, 75, 560–565.PubMedCrossRef
9.
Smolen, J. S., Breedveld, F. C., Burmester, G. R., Bykerk, V., Dougados, M., Emery, P., Kvien, T. K., Navarro-Compan, M. V., Oliver, S., Schoels, M., et al. (2016). Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Annals of the Rheumatic Diseases, 75, 3–15.PubMedCrossRef
10.
Nikiphorou, E., Radner, H., Chatzidionysiou, K., Desthieux, C., Zabalan, C., van Eijk-Hustings, Y., Dixon, W. G., Hyrich, K. L., Askling, J., & Gossec, L. (2016). Patient global assessment in measuring disease activity in rheumatoid arthritis: A review of the literature. Arthritis Research & Therapy, 18, 251.CrossRef
11.
Prevoo, M. L., t’Hof, M. A., Kuper, H. H., van Leeuwen, M. A., van De Putte, L. B., & van Riel, P. L. (1995). Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis and Rheumatism, 38, 44–48.PubMedCrossRef
12.
Aletaha, D., & Smolen, J. (2005). The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): A review of their usefulness and validity in rheumatoid arthritis. Clinical and Experimental Rheumatology, 23, S100–S108.PubMed
13.
Oderda, G. M., & Balfe, L. M. (2011). Comparative effectiveness research (CER): A summary of AHRQ’s CER on therapies for rheumatoid arthritis. Journal of Managed Care Pharmacy, 17, S19–S24.PubMedCrossRef
14.
Bingham, C. O., 3rd., Alten, R., Bartlett, S. J., Bykerk, V. P., Brooks, P. M., Choy, E., Christensen, R., Furst, D. E., Hewlett, S. E., Leong, A., et al. (2011). Identifying preliminary domains to detect and measure rheumatoid arthritis flares: Report of the OMERACT 10 RA Flare Workshop. Journal of Rheumatology, 38, 1751–1758.PubMedCrossRef
15.
Bykerk, V. P., Lie, E., Bartlett, S. J., Alten, R., Boonen, A., Christensen, R., Furst, D. E., Hewlett, S., Leong, A. L., Lyddiatt, A., et al. (2014). Establishing a core domain set to measure rheumatoid arthritis flares: Report of the OMERACT 11 RA flare Workshop. Journal of Rheumatology, 41, 799–809.PubMedCrossRef
16.
Hewlett, S., Sanderson, T., May, J., Alten, R., Bingham, C. O., 3rd., Cross, M., March, L., Pohl, C., Woodworth, T., & Bartlett, S. J. (2012). “I’m hurting, I want to kill myself”: Rheumatoid arthritis flare is more than a high joint count–an international patient perspective on flare where medical help is sought. Rheumatology (Oxford), 51, 69–76.PubMedCrossRef
17.
Bartlett, S. J., Barbic, S. P., Bykerk, V. P., Choy, E. H., Alten, R., Christensen, R., den Broeder, A., Fautrel, B., Furst, D. E., Guillemin, F., et al. (2017). Content and construct validity, reliability, and responsiveness of the rheumatoid arthritis flare questionnaire: OMERACT 2016 workshop report. Journal of Rheumatology, 44, 1536–1543.PubMedCrossRef
18.
Bartlett, S. J., Bykerk, V. P., Cooksey, R., Choy, E. H., Alten, R., Christensen, R., Furst, D. E., Guillemin, F., Halls, S., Hewlett, S., et al. (2015). Feasibility and domain validation of rheumatoid arthritis (RA) flare core domain set: Report of the OMERACT 2014 RA flare group plenary. Journal of Rheumatology, 42, 2185–2189.PubMedCrossRef
19.
Wyrwich, K. W., Norquist, J. M., Lenderking, W. R., & Acaster, S. (2013). Methods for interpreting change over time in patient-reported outcome measures. Quality of Life Research, 22, 475–483.PubMedCrossRef
20.
Jaeschke, R., Singer, J., & Guyatt, G. H. (1989). Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clinical Trials., 10, 407–415.PubMedCrossRef
21.
Bartlett, S. J., Gutierrez, A. K., Andersen, K. M., Bykerk, V. P., Curtis, J. R., Haque, U. J., Orbai, A. M., Jones, M. R., & Bingham, C. O., 3rd. (2022). Identifying minimal and meaningful change in a patient-reported outcomes measurement information system for rheumatoid arthritis: Use of multiple methods and perspectives. Arthritis Care Res (Hoboken), 74, 588–597.PubMedCrossRef
22.
Wells, G., Beaton, D., Shea, B., Boers, M., Simon, L., Strand, V., Brooks, P., & Tugwell, P. (2001). Minimal clinically important differences: Review of methods. Journal of Rheumatology, 28, 406–412.PubMed
23.
Beaton, D., Maxwell, L., Grosskleg, S., Shea, B., Tugwell, P. S., Bingham, C. O., III., Conaghan, P., D’Agostino, M. A., Hofstetter, C., March, L., et al. (2021). The OMERACT Handbook 2.1. Ottawa: OMERACT.
24.
U.S. Food and Drug Administration. Discussion Document for Patient-Focused Drug Development Public Workshop on Guidance 3: Select, Develop, or Modify Fit-for-purpose Clinical Outcome Assessments. In Methods to Identify What is Important to Patients & Select, Develop or Modify Fit-for-Purpose Clinical Outcomes Assessments Rockville, MD; Workshop Date October 15–16, 2018.
25.
Strand, V., & Singh, J. A. (2010). Newer biological agents in rheumatoid arthritis: Impact on health-related quality of life and productivity. Drugs, 70, 121–145.PubMedCrossRef
26.
Bykerk, V. P., Jamal, S., Boire, G., Hitchon, C. A., Haraoui, B., Pope, J. E., Thorne, J. C., Sun, Y., & Keystone, E. C. (2012). The Canadian Early Arthritis Cohort (CATCH): Patients with new-onset synovitis meeting the 2010 ACR/EULAR classification criteria but not the 1987 ACR classification criteria present with less severe disease activity. Journal of Rheumatology, 39, 2071–2080.PubMedCrossRef
27.
Patrick, D. L., Burke, L. B., Gwaltney, C. J., Leidy, N. K., Martin, M. L., Molsen, E., & Ring, L. (2011). Content validity–establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: Part 2–assessing respondent understanding. Value Health, 14, 978–988.PubMedCrossRef
28.
Reeve, B. B., Wyrwich, K. W., Wu, A. W., Velikova, G., Terwee, C. B., Snyder, C. F., Schwartz, C., Revicki, D. A., Moinpour, C. M., McLeod, L. D., et al. (2013). ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Quality of Life Research, 22, 1889–1905.PubMedCrossRef
29.
US Food and Drug Administration. (2020). Principles for selecting, developing, modifying, and adapting patient-reported outcome instruments for use in medical device evaluation; Draft Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders, vol. FDA-2020-D-1564. pp. 53820–53822. Food and Drug Administration, Health and Human Services, Docket No. FDA-2020-D-1564; Document Number:2022-01377. https://​www.​fda.​gov/​media/​141565/​download.
30.
Bartlett, S. J., Bykerk, V. P., Fautrel, B., Guillemin, F., den Broeder, A., Alten, R., Christensen, R., Choy, E., Furst, D., Hewlett, S., et al. (2017). The RA Flare Questionnaire (RA-FQ) is responsive to change in ra symptoms and impacts in clinical and observational trials. Annals of the Rheumatic Diseases, 76, 470–470.
31.
Bykerk, V. P., Bingham, C. O., Choy, E. H., Lin, D., Alten, R., Christensen, R., Furst, D. E., Hewlett, S., Leong, A., March, L., et al. (2016). Identifying flares in rheumatoid arthritis: Reliability and construct validation of the OMERACT RA Flare Core Domain Set. RMD Open, 2, e000225.PubMedPubMedCentralCrossRef
32.
Scott, I. C., & Scott, D. L. (2014). Joint counts in inflammatory arthritis. Clinical and Experimental Rheumatology, 32, 7–12.
33.
Sokka, T., & Pincus, T. (2009). Joint counts to assess rheumatoid arthritis for clinical research and usual clinical care: advantages and limitations. Rheumatic Disease Clinics North America, 35, 713–722.CrossRef
34.
Aletaha, D., & Smolen, J. S. (2007). The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Practice & Research Clinical Rheumatology, 21, 663–675.CrossRef
35.
Dhaon, P., Das, S. K., Srivastava, R., & Dhakad, U. (2018). Performances of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) appear to be better than the gold standard Disease Assessment Score (DAS-28-CRP) to assess rheumatoid arthritis patients. International Journal of Rheumatic Diseases, 21, 1933–1939.PubMedCrossRef
36.
Yun, H., Chen, L., Xie, F., Patel, H., Boytsov, N., Zhang, X., & Curtis, J. R. (2020). Do patients with moderate or high disease activity escalate rheumatoid arthritis therapy according to treat-to-target principles? results from the rheumatology informatics system for effectiveness registry of the American College of Rheumatology. Arthritis Care & Research, 72, 166–175.CrossRef
37.
Goldsmith, C. H., Boers, M., Bombardier, C., & Tugwell, P. (1993). Criteria for clinically important changes in outcomes: Development, scoring and evaluation of rheumatoid arthritis patient and trial profiles OMERACT Committee. The Journal of Rheumatology, 20, 561–565.PubMed
38.
Farrar, J. T., Young, J. P., Jr., LaMoreaux, L., Werth, J. L., & Poole, M. R. (2001). Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain, 94, 149–158.PubMedCrossRef
39.
Salaffi, F., Stancati, A., Silvestri, C. A., Ciapetti, A., & Grassi, W. (2004). Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. European Journal of Pain, 8, 283–291.PubMedCrossRef
40.
Terwee, C. B., Peipert, J. D., Chapman, R., Lai, J.-S., Terluin, B., Cella, D., Griffith, P., & Mokkink, L. B. (2021). Minimal important change (MIC): A conceptual clarification and systematic review of MIC estimates of PROMIS measures. Quality of Life Research, 30, 2729–2754.PubMedPubMedCentralCrossRef
41.
Starfield, B., Wray, C., Hess, K., Gross, R., Birk, P. S., & D’Lugoff, B. C. (1981). The influence of patient-practitioner agreement on outcome of care. American Journal of Public Health, 71, 127–131.PubMedPubMedCentralCrossRef
42.
Rohekar, G., & Pope, J. (2009). Test-retest reliability of patient global assessment and physician global assessment in rheumatoid arthritis. Journal of Rheumatology, 36, 2178–2182.PubMedCrossRef
43.
Desthieux, C., Hermet, A., Granger, B., Fautrel, B., & Gossec, L. (2016). Patient-physician discordance in global assessment in rheumatoid arthritis: A systematic literature review with meta-analysis. Arthritis Care Res (Hoboken), 68, 1767–1773.PubMedCrossRef
44.
Beaton, D. E., Bombardier, C., Katz, J. N., Wright, J. G., Wells, G., Boers, M., Strand, V., & Shea, B. (2001). Looking for important change/differences in studies of responsiveness. OMERACT MCID Working. Group Outcome Measures in Rheumatology. Minimal Clinically Important Difference. J Rheumatol., 28, 400–405.PubMed
45.
Curtis, J. R., Yang, S., Chen, L., Pope, J. E., Keystone, E. C., Haraoui, B., Boire, G., Thorne, J. C., Tin, D., Hitchon, C. A., et al. (2015). Determining the minimally important difference in the clinical disease activity index for improvement and worsening in early rheumatoid arthritis patients. Arthritis Care Res (Hoboken), 67, 1345–1353.PubMedCrossRef
46.
Anderson, J., Caplan, L., Yazdany, J., Robbins, M. L., Neogi, T., Michaud, K., Saag, K. G., O’Dell, J. R., & Kazi, S. (2012). Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken), 64, 640–647.PubMedCrossRef
47.
Bykerk, V. P., Akhavan, P., Hazlewood, G. S., Schieir, O., Dooley, A., Haraoui, B., Khraishi, M., Leclercq, S. A., Legare, J., Mosher, D. P., et al. (2012). Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. Journal of Rheumatology, 39, 1559–1582.PubMedCrossRef
48.
Crosby, R. D., Kolotkin, R. L., & Williams, G. R. (2003). Defining clinically meaningful change in health-related quality of life. Journal of Clinical Epidemiology, 56, 395–407.PubMedCrossRef
Metagegevens
Titel
“From Where I Stand”: using multiple anchors yields different benchmarks for meaningful improvement and worsening in the rheumatoid arthritis flare questionnaire (RA-FQ)
Auteurs
Susan J. Bartlett
Vivian P. Bykerk
Orit Schieir
Marie-France Valois
Janet E. Pope
Gilles Boire
Carol Hitchon
Glen Hazlewood
Louis Bessette
Edward Keystone
Carter Thorne
Diane Tin
Clifton O. Bingham III
CATCH Investigators
Publicatiedatum
08-09-2022
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 5/2023
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-022-03227-7

Andere artikelen Uitgave 5/2023

A qualitative study to examine meaningful change in physical function associated with weight-loss

  • Open Access
  • Special Section: Methodologies for Meaningful Change

Pre-treatment quality of life in patients with salivary gland cancer in comparison with those of head and neck cancer patients

Establishing thresholds for meaningful within-individual change using longitudinal item response theory

  • Open Access
  • Special Section: Methodologies for Meaningful Change

Introduction to the special section: “Methodologies and considerations for meaningful change”

  • Editorial

Patient-centered care in Coronary Heart Disease: what do you want to measure? A systematic review of reviews on patient-reported outcome measures

  • Open Access
  • Review

Do mothers or females without children have better health-related quality of life across their reproductive years?